Core Laboratories Inc.

NYSE:CLB 株式レポート

時価総額：US$642.6m

Core Laboratories 将来の成長

Future 基準チェック /26

Core Laboratoriesは、18.3%と2.5%でそれぞれ年率18.3%で利益と収益が成長すると予測される一方、EPSはgrowで18.5%年率。

主要情報

18.3%

収益成長率

18.51%

EPS成長率

Energy Services 収益成長21.2%
収益成長率2.5%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日18 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 23

CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E

Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).
ナラティブの更新 • Apr 28

CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes

Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).
ナラティブの更新 • Apr 14

CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions

Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).
Seeking Alpha • Mar 26

Core Laboratories: Profit Margins Are Too Small To Get Excited About

Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking Alpha
ナラティブの更新 • Jan 26

CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions

Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.
ナラティブの更新 • Jan 11

CLB: Fair Value View Will Rely On Stabilizing Margins And EPS

Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.
ナラティブの更新 • Dec 14

CLB: Future Earnings And Margins Are Expected To Gradually Stabilize

Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.
分析記事 • Nov 21

A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...
ナラティブの更新 • Sep 10

Middle East And Asia Pacific Markets Will Secure Energy Success

With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.
分析記事 • Sep 10

Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors

Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Jul 24

We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jul 03

Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
分析記事 • Jun 12

Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?

Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...
分析記事 • Apr 04

Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings

With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...
分析記事 • Jan 21

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...
分析記事 • Jan 03

Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...
分析記事 • Dec 09

Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture

To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...
分析記事 • Nov 12

Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
User avatar
新しいナラティブ • Sep 24

New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges

Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.
分析記事 • Sep 19

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?

Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...
分析記事 • Aug 14

What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...
分析記事 • Jul 15

We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 25

These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong

To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...
分析記事 • May 02

It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year

Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...
分析記事 • Mar 26

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?

Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...
分析記事 • Mar 02

Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price

Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...

業績と収益の成長予測

NYSE:CLB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202754837N/AN/A2
12/31/202652121N/AN/A1
3/31/2026525291834N/A
12/31/2025527302237N/A
9/30/2025518323450N/A
6/30/2025517303954N/A
3/31/2025518284458N/A
12/31/2024524314356N/A
9/30/2024523264455N/A
6/30/2024514243042N/A
3/31/2024511382233N/A
12/31/2023510371425N/A
9/30/202350941919N/A
6/30/2023510391525N/A
3/31/202350324616N/A
12/31/2022490191525N/A
9/30/202248715619N/A
6/30/202247991125N/A
3/31/2022477102134N/A
12/31/2021470202337N/A
9/30/202145931518N/A
6/30/2021446331526N/A
3/31/2021443193244N/A
12/31/2020487-974558N/A
9/30/2020530-1017791N/A
6/30/2020598-807996N/A
3/31/2020651-556686N/A
12/31/201966894N/A90N/A
9/30/201968592N/A106N/A
6/30/201969490N/A104N/A
3/31/201970096N/A114N/A
12/31/201870180N/A112N/A
9/30/201869893N/A120N/A
6/30/201867891N/A126N/A
3/31/201866187N/A118N/A
12/31/201764881N/A124N/A
9/30/201762775N/A102N/A
6/30/201760871N/A107N/A
3/31/201759867N/A116N/A
12/31/201659065N/A132N/A
9/30/201662864N/A158N/A
6/30/201668281N/A167N/A
3/31/201673899N/A186N/A
12/31/2015798115N/A219N/A
9/30/2015893166N/A268N/A
6/30/2015972199N/A299N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLBの予測収益成長率 (年間18.3% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: CLBの収益 ( 18.3% ) はUS市場 ( 17% ) よりも速いペースで成長すると予測されています。

高成長収益: CLBの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: CLBの収益 ( 2.5% ) US市場 ( 11.8% ) よりも低い成長が予測されています。

高い収益成長: CLBの収益 ( 2.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/29 21:51
終値2026/05/29 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Core Laboratories Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30

アナリスト機関
James WestBarclays
Nicholas GreenBernstein
Saurabh PantBofA Global Research